國家衛生研究院 NHRI:Item 3990099045/16249

NHRI > Institute of Biomedical Engineering and Nanomedicine > Feng-Huei Lin > Periodical Articles > Item 3990099045/16249

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/16249

Title:	Enhancing intrinsic TGF-beta signaling via heparan sulfate glycosaminoglycan regulation to promote mesenchymal stem cell capabilities and chondrogenesis for cartilage repair
Other Titles:	Enhancing intrinsic TGF-β signaling via heparan sulfate glycosaminoglycan regulation to promote mesenchymal stem cell capabilities and chondrogenesis for cartilage repair
Authors:	Chung, PH;Lin, FH;Liu, IH
Contributors:	Institute of Biomedical Engineering and Nanomedicine
Abstract:	Osteoarthritis burdens patients due to the limited regenerative capacity of chondrocytes. Traditional cartilage repair often falls short, necessitating innovative approaches. Mesenchymal stem cells (MSCs) show promise for regeneration. Heparan sulfate glycosaminoglycans (HS-GAGs) regulate cellular functions, making them a target for cartilage repair. This study highlights how Heparinase III (HepIII) cleaves intact HS-GAGs in bone marrow-derived MSCs (BM-MSCs), enhancing their capabilities and specifically promoting chondrogenesis. HepIII-treated BM-MSCs cultured in a hanging drop device for three days, significantly increased cell number and aggregation into a cell sphere with early chondrogenesis. HepIII promoted BM-MSCs toward chondrogenesis, increasing type II collagen, intact HS-GAGs, and sulfated GAG content, while upregulating chondrogenic and heparan sulfate proteoglycan genes. Treatment with the TGF-β inhibitor (SB-431542) in HepIII-treated BM-MSCs demonstrated enhanced intrinsic transforming growth factor-β (TGF-β) signaling and fibronectin expression. This approach also boosted BM-MSC self-renewal, immunosuppressive potential, and modified acetylated histone signatures, offering a cost-effective strategy for cartilage repair by addressing inflammation, metabolic changes, and the high costs of traditional TGF-β methods. From the results, HepIII-treated BM-MSCs show potential for use in combination with other biopolymers as injectable gels to improve cartilage repair in osteoarthritis patients in the near future.
Date:	2024-11-04
Relation:	International Journal of Biological Macromolecules. 2024 Nov 04;Article in Press.
Link to:	http://dx.doi.org/10.1016/j.ijbiomac.2024.137242
Appears in Collections:	[Feng-Huei Lin] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB39505166.pdf		13820Kb	Adobe PDF	23	View/Open

Loading...